Flow and Iron for Pharma
The status, timeline and source of this project. A free account opens every field.
Source: EU Funding & Tenders Portal
The demand for sustainable methods to build chemical bonds has led to the rise of catalytic reactions, especially using abundant and benign metals. In this context, iron has emerged as a powerful catalyst to mediate various transformations including cross-couplings between (pseudo)halide electrophilic partners and organometallic nucleophiles, usually Grignard reagents. We aim to develop a modular
- Status
- Closed
- Sector
- Education, Chemical (Industrial), Manufacturing (Industrial), Metal, Commercial, Government
- Location
- Belgium
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Flow and Iron for Pharma
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
Sponsoring Agency |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | The demand for sustainable methods to build chemical bonds has led to the rise of catalytic reactions, especially using abundant and benign metals. In this context, iron has emerged as a powerful catalyst to mediate various transformations including cross-couplings between (pseudo)halide electrophilic partners and organometallic nucleophiles, usually Grignard reagents. We aim to develop a modular and versatile Flow-enabled Iron-catalysed cross-coupling protocol for Pharmaceutical applications (FI4P), leveraging the unique properties of flow chemistry to implement cross-couplings between organolithium derivatives and electrophiles. Building on the significant expertise of the academic host in this field, we will seek to harness flow technology to exert spatiotemporal control over reactive intermediates, thus ensuring the functionalisation of halide precursors with reactive lithium organyls generated in situ. The particularly high reaction rates observed in iron-catalysed cross-couplings will allow the incorporation of valuable functional groups usually incompatible with organolithium derivatives. This approach will deliver a sustainable method to assemble relevant molecular scaffolds of interest to the pharmaceutical industry. With the involvement of NovAliX, an industrial partner specialised in transferring academic innovations into industrial processes, we will eventually apply our synthetic protocol to the large-scale manufacture of valuable APIs and the generation of a small collection of molecules designed to complement our existing library for Fragment Based Drug Design. |
Location
Country | Belgium |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Education, Chemical (Industrial), Manufacturing (Industrial), Metal, Commercial, Government |
Article published date | 2026-02-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
